Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013′s ‘Top Oncology Projects to Watch’
Recognition marks significant industry honor for Genelux proprietary vaccinia-based platform technology
SAN DIEGO, Nov. 18, 2013 /PRNewswire/ — Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company’s lead product candidate, GL-ONC1, has been selected by Elsevier Business Intelligence as one of its 2013 “Top 10 Oncology Projects to Watch.” Genelux will present its vaccinia-based proprietary platform technology at the Elsevier Business Intelligence Therapeutic Area Partnerships (TAP) Conference, one of the pharmaceutical industry’s premier partnering events, November 18-20 in Boston.
“Selection as a ‘Top 10 Oncology Project to Watch’ by Elsevier represents a significant industry honor,” said Dr. Aladar Szalay, Founder, President and CEO of Genelux Corporation. “We are very proud of the progress we have made in developing GL-ONC1 for the diagnosis and treatment of a number of difficult-to-treat cancers, as well as our exciting pipeline of future product candidates. Our team looks forward to discussing the science behind the Genelux oncolytic vaccinia-based platform, the GL-ONC1 program and the Company’s future plans at the TAP conference.”
Elsevier considered various criteria when selecting the Top 10 Programs, including the history of the molecule or drug, the diversity of indications – initial and future, and multi-level partnering prospects. “Select companies have been screened using a strict set of judging criteria for the Top 10 awards and represent what our committees consider among the most attractive opportunities the industry has to offer,” said David Cassak, Vice President, Content, Elsevier Business Intelligence. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.” More details can be found at http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.
Dr. Tony Yu, Vice President of Clinical Trial Operations, will be presenting on behalf of the company. His presentation is at 10:30 AM EST, Tuesday, Nov. 19.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and “The Pink Sheet.” For more information, visit: http://www.ElsevierBi.com.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific diagnostic and/or therapeutic genes for delivery and amplification in cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com.
Genelux Forward Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management’s current beliefs and assumptions founded on the data and information currently available to us. Statements of the company’s progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.
Read more news from Genelux.
SOURCE Genelux Corporation